home / stock / galt / galt news

GALT News and Press, Galectin Therapeutics Inc. From 03/14/24

Stock Information
Company Name: Galectin Therapeutics Inc.
Stock Symbol: GALT
Market: NASDAQ
Website: galectintherapeutics.com
Menu
GALT GALT Quote GALT Short GALT News GALT Articles GALT Message Board
Get GALT Alerts

News, Short Squeeze, Breakout and More Instantly...
GALT - Madrigal wins FDA approval for NASH therapy

2024-03-14 15:45:17 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...
GALT - Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy

2024-03-14 10:42:03 ET More on Madrigal Pharma Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potentia...

GALT - Liver drug developers outperform as U.S. awaits first NASH drug

2024-03-13 13:29:04 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...

GALT - Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost tw...
GALT - Galectin Therapeutics GAAP EPS of -$0.24

2023-11-13 14:31:34 ET More on Galectin Therapeutics Galecto Biotech Collapse: Opportunity For Galectin Therapeutics Seeking Alpha’s Quant Rating on Galectin Therapeutics Historical earnings data for Galectin Therapeutics Financial information for Gale...

GALT - UPDATE - Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are in...

GALT - Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are in...
GALT - Expected US Company Earnings on Monday, November 13th, 2023

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

GALT - Expected earnings - Galectin Therapeutics Inc.

Galectin Therapeutics Inc. (GALT) is expected to report $-0.16 for Q3 2023

GALT - Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting(TM) 2023, Hosted by the AASLD

Pharmacokinetics and safety of belapectin in patients with hepatic insufficiency Lack of impact of belapectin on cardiac repolarization (QT interval) Very High Elevation of Gamma-Glutamyl Transpeptidase (GGT) as a new marker of disease progression in patient with portal hypertensi...
Previous 10 Next 10